TNFSF10 and thyroid gland carcinoma: In vitro studies have demonstrated that tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) or TRAIL antibodies, when combined with sorafenib, synergistically reduce cell growth and increase cell death in solid tumor cell lines, including breast, prostate, colon, liver, and thyroid cancers [108].